Neurosense Therapeutics Ltd. (NRSN) AI Stock Analysis

• Market Cap: $23.00M
• Dividend Yield: N/A
• Average Volume (3M): 154.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: N/A
• EPS Growth: 24.35%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 23,228,941
• 10 Day Avg. Volume: 141,430
• 30 Day Avg. Volume: 154,076
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.50
• Price Target Upside: 657.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Neurosense Therapeutics Ltd. receives a low overall score due to severe financial challenges, including the lack of revenue and profitability, and a weak balance sheet. While technical analysis suggests a neutral trend, the negative valuation metrics highlight the financial risks. The company's dependency on external financing without clear revenue streams presents significant uncertainty for investors.

Positive Factors

Commercialization strategy

NeuroSense announced plans to pursue early commercialization of PrimeC for ALS in Canada, potentially allowing revenue and cash flow before U.S. approval.

Regulatory approval

Canadian regulatory authorities may be less strict on conditional approval requirements, increasing the possibility of success for PrimeC.

Negative Factors

Financing challenges

Capital constraints, including “baby shelf” limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.

Neurosense Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Neurosense Therapeutics Ltd. (NRSN) is a biotechnology company focused on the development of treatments for neurodegenerative diseases. The company is engaged in discovering and developing novel therapeutic solutions aimed at addressing significant unmet medical needs. Its core product pipeline includes drug candidates targeting conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, leveraging innovative approaches to modify disease progression and improve patient outcomes.

How the Company Makes Money

Neurosense Therapeutics Ltd. primarily generates revenue through the development and commercialization of its pharmaceutical products. The company invests in research and development to advance its drug candidates through clinical trials, seeking regulatory approval to bring these therapies to market. Revenue streams include potential licensing agreements, milestone payments, and royalties from partnerships with larger pharmaceutical companies interested in co-developing or marketing Neurosense's drug candidates. Additionally, the company might generate income through grants, research collaborations, and potential future sales of approved products. Key factors contributing to its earnings include successful clinical trial outcomes, strategic alliances, and the ability to secure intellectual property rights for its innovations.

Neurosense Therapeutics Ltd. Financial Statement Overview

Summary

Neurosense Therapeutics Ltd. faces significant financial challenges, characterized by a lack of revenue, consistent operational losses, and a weak balance sheet. The company struggles with cash flow management, relying on external financing. To improve its financial health, the company needs to establish revenue streams and stabilize its cash flow.

Income Statement

Neurosense Therapeutics Ltd. has no revenue streams, resulting in negative gross profit and net income over the years. The company consistently operates at a loss, with EBIT and EBITDA margins being negative. The absence of revenue and declining net income indicates significant challenges in achieving profitability.

Balance Sheet

The company has a weak balance sheet with negative stockholders' equity in recent years, indicating potential issues with financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, emphasizing the need for improved financial structure. Total liabilities exceed total assets, posing a risk to financial solvency.

Cash Flow

Neurosense Therapeutics Ltd. is experiencing negative free cash flow, with operating cash flow consistently negative. The free cash flow growth is volatile with significant fluctuations, highlighting cash management challenges. The company relies heavily on financing activities to manage its cash flow requirements.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-97.00K	-89.00K	―	―	0.00
	EBIT
-12.65M	-12.05M	-13.55M	-5.59M	-2.89M	-1.24M
	EBITDA
-12.87M	-10.63M	-13.38M	-2.88M	-2.83M	-1.25M
	Net Income Common Stockholders
-12.79M	-10.11M	-11.20M	-2.50M	-2.83M	-1.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
895.00K	2.64M	7.09M	11.06M	699.00K	895.00K
	Total Assets
0.00	3.18M	7.71M	11.43M	779.00K	955.00K
	Total Debt
0.00	142.00K	211.00K	1.83M	0.00	0.00
	Net Debt
895.00K	-2.50M	-3.33M	-9.23M	-699.00K	-895.00K
	Total Liabilities
0.00	5.05M	2.09M	2.42M	120.00K	37.00K
	Stockholders Equity
918.00K	-1.87M	5.62M	9.01M	659.00K	918.00K
Cash Flow		Free Cash Flow
1.78K	-8.48M	-7.66M	-1.56M	-704.00K	-589.00K
	Operating Cash Flow
1.78K	-8.45M	-7.59M	-1.54M	-695.00K	-582.00K
	Investing Cash Flow
0.00	3.47M	-3.54M	-17.00K	-9.00K	-26.00K
	Financing Cash Flow
0.00	3.90M	3.69M	11.90M	508.00K	1.42M

Neurosense Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.09, and below the 200-day MA of 1.06, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 28.95 is Positive, neither overbought nor oversold. The STOCH value of 14.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRSN.

Neurosense Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	76 Outperform	$2.57B	11.31	38.89%	―	31.85%	―
NBIX	68 Neutral	$9.54B	29.06	14.16%	―	24.81%	33.67%
AXSM	51 Neutral	$4.82B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
SAGE	48 Neutral	$421.76M	―	-63.37%	―	-52.30%	27.13%
BTAI	39 Underperform	$8.94M	―	82.91%	―	64.20%	73.71%
NRSN	28 Underperform	$23.00M	―	539.33%	―	―	24.35%